Although a number of studies have now shown value of an EGFR-AURKA combination in EGFR-mutated or -overexpressing cancers, the question of whether this combination may have activity in lung tumors that do not contain EGFR driver mutations has not been addressed. Here, EGFR is linked to cancer.